Vericel Corp

Vericel Corporation provides advanced therapies for sports medicine and severe burn care markets. The company offers a portfolio of cell therapy and specialty biologic products. Vericel markets two U.S. Food and Drug Administration ("FDA") approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous cellularized scaffold product for repairing symptomatic, single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. MACI's FDA-approved labeling initially provided for treatment through an open surgical procedure. In August 2024, the FDA approved a supplemental Biologics License Application ("sBLA") expanding the MACI indication to include instructions for arthroscopic delivery. MACI Arthro® allows surgeons to evaluate and prepare the cartilage defect site and deliver the MACI implant through small incisions using custom-designed arthroscopic instruments developed by the Company ("MACI Arthro instruments"). MACI Arthro became commercially available in the U.S. during the third quarter of 2024, and the Company began selling MACI Arthro instruments at that time. Epicel® is a permanent skin replacement Humanitarian Use Device ("HUD") for treating adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of a patient's total body surface area ("TBSA"). Vericel also holds an exclusive license from MediWound Ltd. for the North American rights to NexoBrid® (anacaulase-bcdb), a topically-administered biological orphan product containing proteolytic enzymes, indicated for the removal of eschar in adult and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.